Session 1: Molecular biomarkers and novel imaging in APC
Talk 2: Clinical utility of molecular markers
De Bono
Talk 3: Advantages and pitfalls of PSMA PET/CT in APC imaging - Advantages
Fanti
Talk 4: Advantages and pitfalls of PSMA PET/CT in APC imaging - Pitfalls
Davis
Session 2: Node-positive prostate cancer (N1 but M0)
Talk 1: Node-positive prostate cancer (N1 but M0) - Surgery Options
Murphy
Talk 2: Node-positive prostate cancer (N1 but M0) - Radiation therapy options
Roach
Talk 3: Node-positive prostate cancer (N1 but M0) - Systematic therapy options
James
Talk 4: Synthesis – How best to treat cN1 prostate cancer
Fizazi
Talk 5: How to treat men with pathological node positive (pN1, cM0) prostate cancer?
Bossi
Session 3: PSA recurrence after radical local therapy and oligometastatic prostate cancer
Talk 1: Management of men with PSA recurrence after radical local radiation therapy
Feng
Talk 2: Management of men with PSA recurrence or persistence after prostatectomy
Evans
Talk 3: Oligometastatic prostate cancer – Definitions and concepts
Reiter
Talk 4: Treatment of de novo (synchronous) oligometastatic prostate cancer
Morris
Talk 5: Treatment of oligorecurrent (metachronous) prostate cancer after local therapy
Ost
Talk 6: Treatment of oligometastatic and oligoprogressive CRPC
Small
Session 4: Regional care (demographic and environmental factors)
Talk 1: Ethnicity and prognosis
Logothetis
Talk 2: Pharmaco-ethnicity and impact on treatment
Poon
Talk 3: Report and lessons learned from the consensus conference for developing countries
Maluf
Talk 4: Disparities in prostate cancer management in the U.S.
Morgans
Talk 5: The ageing population: Oncogeriatric assessment and treatment considerations
O'Sullivan
Extra Session: Movember
Outcomes Research – Ironman project
Morgans, Davis
Session 5: Management of metastatic castration-sensitive/naive prostate cancer
Talk 1: Testosterone measurement – Which test and when?
Gleave
Talk 2: Local treatment of the primary tumour (RT) in the metastatic situation
Bristow
Talk 3: Local treatment of the primary tumour (surgery) in the metastatic situation
Steuber
Talk 5: Addition of AR pathway inhibitors vs. docetaxel: Statisticians’ perspective
Sydes
Talk 6: Follow-up on ADT alone vs. ADT “plus”
Oh
Session 6: Management of castration-resistant prostate cancer (CRPC)
Talk 1: Definition and overview of treatment options in nmCRPC
Scher
Talk 2: Debate: Treatment of nmCRPC - Pros
Hussain
Talk 3: Debate: Treatment of nmCRPC - Cons
Higano
Talk 4: First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor
Taplin
Talk 5: Subgroup analysis of mCRPC clinical trials
Halabi
Talk 6: PSMA targeted therapies
Hofman
Talk 9: Neuroendocrine spectrum: Diagnosis and treatment
Efstathiou
Session 7: Side effects of treatment and their management
Talk 1: Management of sexuality and incontinence issues in APC
Van Oort
Talk 2: Management of hot flushes
Frydenberg
Talk 3: Management of metabolic changes
Shore
Talk 4: Management of fatigue, cognition/dementia
Ryan
Talk 5: Optimal steroid use with abiraterone
Attard
Session 8: Bone and bone metastases
Talk 1: Prevention/Treatment of osteoporosis
Saad
Talk 5: Radium-223 and bone health agents
Sartor
Talk 6: The flare phenomenon in bone-metastatic APC
Padhani
Session 9: The future of APC management
Talk 1: Wishes from a patient’s perspective
Millman
Talk 2: In locally advanced prostate cancer
Briganti
Talk 3: Looking into the Future: Oligometastatic Disease
Beltran
Talk 4: In polymetastatic prostate cancer
Oh
Talk 7: Global access to treatments
Fizazi